Medigene AG: New research collaborations and additional grant for immunotherapy TABs
(Thomson Reuters ONE) -
Medigene AG /
Medigene AG: New research collaborations and additional grant for immunotherapy
TABs
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
Press Release
* New research collaborations with Max Delbrück Centre for Molecular Medicine
and Helmholtz Zentrum München entered
* Public funding by German Federal Ministry of Education and Research within
"m(4) Cluster Initiative" increased
Martinsried/Munich, 22 September, 2014. Medigene AG (MDG1, Frankfurt, Prime
Standard) announces that its subsidiary Trianta Immunotherapies GmbH entered two
new research collaborations for further development of its immunotherapy
platform TABs (T-cell-specific AntiBodies) for the treatment of various types of
cancer and autoimmune diseases. In the future, scientists of the Max Delbrück
Center for Molecular Medicine (MDC) and the Helmholtz Zentrum München - German
Research Center for Environmental Health, Munich (HMGU) will undertake single
research and development tasks in this special field.
Preclinical in vivo data about the treatment of autoimmune diseases and T cell
leukemia with monoclonal antibodies generated during the granted period will be
of great value for further clinical development of this immunotherapy platform.
Overall, the collaboration with both research institutions offers Medigene
extended scientific synergies regarding technology transfer, infrastructure and
exchange of knowledge.
Additionally, Trianta will receive increased public funding for its
immunotherapy platform TABs. The grant which has already been awarded by the
Federal Ministry of Education and Research, (Bundesministerium für Bildung und
Forschung = BMBF) within the scope of the "m(4) - Personalized Medicine and
Targeted Therapies: a new Dimension of Drug Development" Munich Leading-Edge
Cluster initiative in beginning of June, now has been increased. The sponsored
project intends to provide evidence of the elimination of pathogenic T cells in
T-cell leukemia and autoimmune diseases, applying in-vivo and in-vitro methods
with T-cell receptor-specific monoclonal antibodies. The project is financed by
Medigene (60%) as well as the BMBF grant (40%).
About the leading-edge cluster "m4 - Personalised Medicine and Targeted
Therapies":
The project is funded by the program 'm4 - Personalised Medicine and Targeted
Therapies' for which the Munich Biotech Cluster was awarded 'Leading-Edge
cluster status' by the German Federal Ministry of Research and Education (BMBF)
in 2010. For a 5 year period, the program is funded with EUR 40 million from the
BMBF, which are complemented by EUR 40 million from the participating companies
in more than 50 cooperative R&D projects from industry and scientific
institutions. The Bavarian Ministry of Economic Affairs and Media, Energy and
Technology supports the cluster management agency BioM and in particular the m4
pre-seed concept with an additional EUR 12 million. For more information please
visit http://www.m4.de/.
About Anti-TCR monoclonal antibodies (TABs): The TABs immunotherapy platform
serves to generate monoclonal antibodies which recognise different T cells based
on their T cell receptors (TABs = T cell-specific antibodies). These TABs are
intended to remove unwanted cells from the body in order to treat T cell-induced
diseases such as T cell leukaemia or various autoimmune diseases. Monoclonal
antibodies which are able to distinguish between different T cell receptors have
already been produced and characterised. Proof of technology was established in
preclinical experiments.
About Trianta: Based on more than 15 years of extensive research in the field of
immunotherapy, Trianta Immunotherapies GmbH was founded late 2013 as a spin-off
of the Helmholtz Zentrum München and was acquired by Medigene as a 100%
subsidiary in January 2014. Trianta pursues three complementary
immunotherapeutic strategies to target various tumour types and stages: next
generation antigen-tailored dendritic cell (DC) vaccines, T cell receptor (TCR)-
based adoptive cell therapy and T cell-targeted antibodies (TABs). Each one is
focused on T cells, a type of white blood cell that plays a pivotal role in
immunity.
Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology
company headquartered in Martinsried near Munich, Germany. Medigene concentrates
on the development of personalized T cell immunotherapies with a focus on
haematological malignancies. Medigene is the first German biotech company to
have revenues from a marketed product, which is distributed by commercial
partner companies. Medigene has advanced drug candidates which are licensed to
partners and additional candidates in clinical development. The company is
developing highly innovative treatment platforms concentrating on cancer and
autoimmune diseases. For more information, please visit www.medigene.com.
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) EndoTAG(®) and Veregen(® )are registered trademarks of Medigene AG.
These trademarks may be owned or licensed in select locations only.
Contact Medigene
Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please visit:
http://www.medigene.de/unsubscribe
Press release as PDF:
http://hugin.info/132073/R/1857216/650234.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via GlobeNewswire
[HUG#1857216]
Unternehmensinformation / Kurzprofil:
Datum: 22.09.2014 - 07:30 Uhr
Sprache: Deutsch
News-ID 342373
Anzahl Zeichen: 7050
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 189 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene AG: New research collaborations and additional grant for immunotherapy TABs"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
